Amendment to Jan 23 06 Warrant - Amendment to Feb 28 06 Warrant
Exhibit
4.3
June
1,
2006
Warrantholder
Attention:
Dear
Sirs:
| Re: |
Generex
Biotechnology
Corporation
|
|
-
|
Amendment
to Jan 23 06 Warrant
|
|
-
|
Amendment
to Feb 28 06 Warrant
|
We
make
reference to (a) the common stock purchase warrant (the “January
Warrant”)
issued
by Generex Biotechnology Corporation (the “Company”)
to
(“___________”) on January 23, 2006 pursuant to which the Company granted to
______________ the entitlement to purchase up to ____________ shares
of the
Company’s common stock at $1.60 per share, and (b) the common stock purchase
warrant (the “February
Warrant”)
issued
by the Company to ___________ on February 28, 2006 pursuant to which
the Company
granted to Cranshire the entitlement to purchase up to __________ shares
of the
Company’s common stock at $1.25 per share (together, the “Warrants”).
The
Initial Exercise Date (as that term is defined in each of the Warrants)
of each
of the Warrants is expressed therein as the 181st
day
after the date thereof. The Company hereby confirms that, in consideration
of
the immediate exercise by Cranshire of not less than 100% of the January
Warrant
(__________ shares for $_______________) and not less than ____% of the
February
Warrant (_________ shares for $__________)1
Cranshire exercised the other 50% of the February Warrant on March 6,
2006.
(together, the “Warrant
Exercises”),
the
delivery to the Company of Notices of Exercise in respect thereof on
or before
the close of business on June 1, 2006, and the payment by Cranshire to
the
Company of an the aggregate subscription price of $________________,
the Company
has agreed to abridge the Initial Exercise Dates and to honor the aforementioned
Notices of Exercise.
In
addition, the Company will grant to Cranshire an additional common stock
purchase warrant pursuant to which the Company will grant to Cranshire
the
entitlement to purchase up to __________ shares of the Company’s common stock at
$2.35 per share exercisable for a period of five years from and after
December
1, 2006.
Yours
truly,
Generex
Biotechnology Corporation
|
▇▇▇▇
▇. ▇▇▇▇▇
|
▇▇▇▇
▇. ▇▇▇▇▇▇▇▇
|
|
Chief
Financial Officer [
|
Executive
Vice-President,
General
Counsel
|
1
Cranshire exercised the other 50% of the February Warrant on March
6,
2006.